Skip to main content
Premium Trial:

Request an Annual Quote

Roche NimbleGen Certifies UK's NewGene to Offer Sequence Capture Services

Premium

By Justin Petrone

Roche this week said that it has certified NewGene to provide sequence capture services on its microarray and sequencing platforms.

As a certified service provider, Newcastle, UK-based NewGene will provide services for NimbleGen sequence capture arrays with next-generation sequencing on the Genome Sequencer FLX System from Roche's 454 Life Sciences business.

NewGene is the first UK-based services provider to join the Roche NimbleGen CSP network. The molecular diagnostics and research services firm is a partnership between the Newcastle Hospitals National Health System Foundation Trust and Newcastle University.

CEO David Huntley said in a statement that the ability to offer sequence capture services will "provide significant scientific, technical, and economic benefits to our UK customers."

In addition to NewGene, Berlin-based Atlas Biolabs and Ebersberg, Germany-based Eurofins MWG Operon are certified to offer NimbleGen sequence capture services in Europe and Aliso Viejo, Calif.-based Ambry Genetics is certified to offer them in North America.

Financial details of the deal with NewGene were not discussed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.